{"gene":"SLC18A2","run_date":"2026-06-10T07:46:32","timeline":{"discoveries":[{"year":1997,"finding":"VMAT2 pumps monoamine neurotransmitters and dopaminergic neurotoxins (MPP+) from neuronal cytoplasm into synaptic vesicles. Heterozygous VMAT2 knockout mice (50% VMAT2 levels) show enhanced amphetamine locomotion, diminished conditioned reward, and >2× dopamine cell loss after MPTP, establishing that vesicular sequestration contributes to neuroprotection and modulates amphetamine behavioral effects.","method":"VMAT2 knockout mouse generation; behavioral assays (conditioned place preference, locomotion); MPTP neurotoxicity with cell counting","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with multiple orthogonal behavioral and neurochemical readouts, replicated in subsequent studies","pmids":["9275230"],"is_preprint":false},{"year":1994,"finding":"VMAT2 (but not VMAT1) is expressed in neurons of the sympathetic nervous system and aminergic neurons in the enteric and central nervous systems, while VMAT1 is restricted to endocrine/paracrine cells; the two isoforms show mutually exclusive expression in peripheral endocrine cells, establishing cell-type-specific patterns of vesicular monoamine storage.","method":"Isoform-specific polyclonal antipeptide antibodies; immunostaining of monkey fibroblasts programmed to express VMAT1 or VMAT2; immunohistochemistry on rat tissues","journal":"Journal of molecular neuroscience : MN","confidence":"High","confidence_rationale":"Tier 2 / Strong — antibody specificity validated by isoform-selective cell expression system; replicated across multiple subsequent studies","pmids":["7654518"],"is_preprint":false},{"year":2000,"finding":"VMAT2 activity in BON serotonergic cells and in serotonergic raphe neurons is down-regulated specifically by the heterotrimeric G-protein Gαo2 (pertussis toxin-sensitive), but not by Gαo1. Electron microscopy showed VMAT2 and Gαo2 co-localizing preferentially on small synaptic vesicles in serotonergic terminals of prefrontal cortex, and Go2-dependent modulation was confirmed in crude synaptic vesicle preparations from this brain area.","method":"Transport assays in BON cells and primary raphe neurons; pertussis toxin treatment; electron microscopic immunocytochemistry; synaptic vesicle preparation uptake assays","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro functional assays with pertussis toxin, EM co-localization, and vesicle preparation uptake, multiple cell systems","pmids":["10704487"],"is_preprint":false},{"year":2003,"finding":"Vesicular filling of VMAT2-containing platelets with serotonin or noradrenaline triggers Gαq-mediated down-regulation of VMAT2 activity, demonstrating an autoregulatory mechanism whereby vesicle content controls transporter activity. Gαq (not serotonergic/noradrenergic/thromboxane receptors) mediates this effect, shown using Gαq knockout platelets.","method":"Streptolysin O-permeabilized platelet transport assays; Tph1−/− (tryptophan hydroxylase knockout) platelet reconstitution; Gαq knockout mouse platelets; GTP analog (GMppNp) activation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution in depleted platelets, genetic KO of Gαq, multiple orthogonal approaches","pmids":["12604601"],"is_preprint":false},{"year":2002,"finding":"Human VMAT2 contains an intramolecular disulfide bond between Cys126 (in lumenal loop 1/2) and Cys333 (in lumenal loop 7/8). Mutation of either cysteine to serine reduced [³H]serotonin transport and eliminated the DTT-reversible covalent bond, indicating this disulfide bond contributes to efficient monoamine transport.","method":"Engineered thrombin cleavage site in deglycosylated HA-tagged human VMAT2; SDS-PAGE under reducing/non-reducing conditions; site-directed mutagenesis (C126S, C333S); [³H]serotonin transport assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with mutagenesis and functional transport assays, direct structural characterization","pmids":["12009896"],"is_preprint":false},{"year":2013,"finding":"The 20-amino-acid N-terminus of VMAT2 regulates monoamine sequestration and methamphetamine-stimulated efflux. PKC phosphorylates the N-terminus at Ser15 and Ser18; phospho-mimetic (S15D/S18D) mutations reduced [³H]-5HT sequestration and abolished methamphetamine-stimulated efflux of pre-loaded substrate, while alanine mutations (S15A/S18A) maintained sequestration but eliminated METH-stimulated efflux.","method":"N-terminal truncation constructs; GST-fusion PKC phosphorylation assay; site-directed mutagenesis (S15D, S18D, S15A, S18A); [³H]-5HT sequestration and efflux assays in transfected cells","journal":"Neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis plus functional transport/efflux assays, single lab but multiple orthogonal methods","pmids":["24321511"],"is_preprint":false},{"year":2014,"finding":"Rotenone inhibits VMAT2 activity (without reducing VMAT2 protein levels) via JNK3, the neural-specific JNK isoform. Rotenone-induced microtubule destabilization activates JNK, which inhibits VMAT2 activity; pharmacological JNK inhibition (SP600125) or incubation of synaptic vesicles with recombinant JNK3 protein directly inhibited VMAT2 activity, placing JNK3 as a novel upstream regulator of VMAT2.","method":"Primary dopamine neuron cultures; JNK isoform-specific knockdown; pharmacological JNK inhibition; in vitro incubation of recombinant JNK3 with purified mesencephalic synaptic vesicles; VMAT2 activity assays","journal":"Toxicology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution of JNK3 inhibition of VMAT2 vesicles, supported by pharmacological and genetic inhibition in neurons","pmids":["25496994"],"is_preprint":false},{"year":2003,"finding":"VMAT2 mutant mice with ~95% reduction in VMAT2 expression have reduced vesicular dopamine stores, lower impulse-dependent DA release, reduced amphetamine-evoked DAT-mediated efflux, and compensatory supersensitivity of D2/D3 release-regulating autoreceptors, demonstrating that VMAT2 levels determine the size of releasable vesicular and cytosolic dopamine pools.","method":"Fast cyclic voltammetry in striatal slices; pharmacological dissection with GBR12935 (DAT blocker), sulpiride (D2/D3 antagonist), quinpirole (agonist); homozygous VMAT2 mutant mice vs. wild-type","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ex vivo voltammetry with multiple pharmacological probes, genetic model, replicated across conditions","pmids":["12716422"],"is_preprint":false},{"year":2016,"finding":"VMAT2 level inversely determines vulnerability to MPTP neurotoxicity: VMAT2-LO mice (95% reduction) show reduced vesicular uptake, progressive dopaminergic terminal loss, and exacerbated MPTP toxicity, while VMAT2-HI (overexpressing) mice are protected from MPTP-induced striatal terminal loss and show altered handling of newly synthesized dopamine.","method":"VMAT2-LO and VMAT2-HI transgenic mice on identical C57BL/6 background; vesicular uptake assays; MPTP treatment with neurochemical and immunohistochemical endpoints","journal":"Toxicological sciences : an official journal of the Society of Toxicology","confidence":"High","confidence_rationale":"Tier 2 / Strong — bidirectional genetic manipulation (KO and OE) with direct vesicular uptake assay and toxin challenge, same genetic background","pmids":["27287315"],"is_preprint":false},{"year":2011,"finding":"VMAT2-deficient mice (95% reduction) develop progressive catecholamine neuron loss in the substantia nigra, locus coeruleus, and dorsal raphe, with α-synuclein accumulation, and display progressive motor deficits, olfactory dysfunction, delayed gastric emptying, anxiety, and depression-like phenotype, establishing that disrupted vesicular monoamine storage is sufficient to produce multi-system neurodegeneration resembling Parkinson's disease.","method":"Conditional VMAT2-deficient mouse model; immunohistochemistry; behavioral battery; stereological cell counting; α-synuclein staining","journal":"Parkinson's disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic model with comprehensive neurochemical and behavioral phenotyping, replicated across multiple labs","pmids":["21403896"],"is_preprint":false},{"year":2013,"finding":"VMAT2 inhibition by reserpine or tetrabenazine promotes late-stage differentiation of Pdx1-positive pancreatic progenitors into Ngn3-positive endocrine precursors and subsequently into β cells. VMAT2-controlled monoamines (dopamine, histamine, serotonin) negatively regulate β-cell differentiation; ES cell-derived β cells produced by this protocol reversed hyperglycemia in diabetic mice upon transplantation.","method":"Chemical screening with VMAT2 inhibitors; ES cell differentiation assays; glucose-stimulated insulin secretion; transplantation into AKITA diabetic mice","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional differentiation assay with pharmacological VMAT2 inhibition, in vivo transplantation validation, multiple orthogonal readouts","pmids":["24316738"],"is_preprint":false},{"year":2020,"finding":"VMAT2 in pancreatic β-cells sequesters dopamine into vesicles to protect it from monoamine oxidase-mediated degradation, thereby limiting reactive oxygen species (ROS) generation. β-cell-specific Vmat2 knockout mice show elevated insulin secretion under glucose stimulation but, under prolonged high-fat diet, exhibit impaired glucose tolerance, progressive β-cell dysfunction, elevated ROS, accelerated β-cell dedifferentiation and loss.","method":"β-cell-specific Vmat2 conditional KO mice; glucose/insulin tolerance tests; ROS measurement; insulin secretion assays; immunostaining for β-cell markers","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific KO with mechanistic ROS assays and functional metabolic phenotyping, multiple orthogonal methods","pmids":["32826296"],"is_preprint":false},{"year":2021,"finding":"Loss of Vmat2 in zebrafish (CRISPR/Cas9 5-bp deletion) reduces dopamine, noradrenaline, serotonin, and histamine levels while increasing monoamine metabolites (elevated turnover), upregulates dopamine-synthesizing enzymes and histidine decarboxylase-expressing neurons, and downregulates Notch1a and Pax2a in brain proliferative zones, demonstrating that Vmat2 controls monoamine turnover and brain developmental gene expression.","method":"CRISPR/Cas9 zebrafish knockout; HPLC monoamine quantification; qPCR; in situ hybridization; immunocytochemistry; behavioral assays","journal":"Acta physiologica (Oxford, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with multiple orthogonal biochemical and molecular readouts in an ortholog model","pmids":["34403568"],"is_preprint":false},{"year":2007,"finding":"During normal aging in rats, VMAT2 undergoes deglycosylation and subcellular redistribution: the three glycosylation forms (75, 55, 45 kDa) virtually disappear from the synaptic vesicle-enriched fraction while the 55 kDa partially glycosylated form accumulates in the soluble compartment, without changes in total VMAT2 protein or mRNA, providing a mechanism for age-related decline of vesicular monoamine uptake.","method":"Subcellular fractionation of rat striatum (synaptosomal membrane and synaptic vesicle fractions); Western blot; in situ hybridization for VMAT2 mRNA; comparison of young vs. aged rats","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — fractionation with functional link to VMAT2 activity decline, single lab, biochemical readout without direct activity confirmation","pmids":["17582657"],"is_preprint":false},{"year":2005,"finding":"Synaptophysin enhances VMAT2-mediated neuroprotection against MPP+ toxicity in MN9D dopaminergic cells. Co-overexpression of VMAT2 and synaptophysin produced synergistic protection, suggesting synaptophysin promotes biogenesis of secretory vesicles and influences VMAT2 targeting to these vesicles.","method":"Stable overexpression of VMAT2 and/or synaptophysin in MN9D cells; MPP+ toxicity assays; cell viability measurements","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — overexpression in cell line with viability assay, single lab, no direct vesicle targeting measurement","pmids":["16023584"],"is_preprint":false},{"year":2012,"finding":"Overexpression of VMAT2 (7-fold increase with GFP fusion) in RCSN-3 substantia nigra-derived cells significantly protects against aminochrome neurotoxicity; synaptic vesicle preparations from rat substantia nigra transport [³H]-aminochrome at rates similar to dopamine (ATP-dependent), with aminochrome uptake inhibited by lobeline but not reserpine, establishing VMAT2 as a protective transporter for aminochrome sequestration.","method":"Bicistronic plasmid overexpression of VMAT2-GFP; [³H]-aminochrome and [³H]-dopamine uptake in synaptic vesicles; transmission electron microscopy; ATP assay; DNA laddering","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro vesicle transport assay plus cell overexpression with functional outcome, single lab","pmids":["22483869"],"is_preprint":false},{"year":2016,"finding":"VMAT2 undergoes retrograde trafficking to the trans-Golgi network in non-neuronal cells and interacts biochemically and subcellularly with Vps35, a key component of the retromer complex. siRNA knockdown of Vps35 alters VMAT2 subcellular localization and decreases VMAT2 protein stability (reduced half-life), identifying retromer-dependent retrograde trafficking as a regulator of VMAT2 stability.","method":"Biochemistry (co-immunoprecipitation); subcellular localization imaging; siRNA knockdown of Vps35; VMAT2 half-life measurement","journal":"Journal of biomedical research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP plus siRNA functional study with localization, single lab, non-neuronal cell system","pmids":["27924069"],"is_preprint":false},{"year":2011,"finding":"Selective knockout of Vmat2 in midbrain leptin receptor (LepR) neurons disrupts dopamine accumulation in vesicles without significantly altering evoked glutamate or GABA release to downstream neurons. Specific activation of midbrain LepR neurons promotes VMAT2-dependent feeding; KO mice resist high-fat diet-induced obesity, establishing that VMAT2-mediated monoamine (dopamine) release from midbrain LepR neurons regulates high-fat diet consumption and leptin's feeding effects.","method":"Conditional Vmat2 KO in LepR-Cre neurons; evoked neurotransmitter release measurement; optogenetic activation; feeding behavior and metabolic phenotyping","journal":"eNeuro","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional KO with optogenetics and feeding behavior, single lab","pmids":["28560316"],"is_preprint":false},{"year":2007,"finding":"Genetic deletion of VMAT2 in dopaminergic neurons (homozygous KO) in primary mesencephalic cultures reduces dopamine transporter (DAT) activity without affecting TH-positive cell number; reserpine (VMAT2 inhibitor) likewise reduces DAT activity in WT and heterozygous cultures but not in homozygous KO cells, establishing that VMAT2 activity is required to maintain normal DAT function.","method":"Primary mesencephalic cultures from VMAT2 wild-type, heterozygous, and homozygous KO mice; DAT activity assays; reserpine pharmacology; synaptosomal DAT assays from neonatal mice","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus pharmacological confirmation, functional transport assay, single lab","pmids":["17664021"],"is_preprint":false},{"year":2017,"finding":"Low-power laser irradiation (LPLI) protects SH-SY5Y cells against MPP+-induced neurotoxicity by activating ERK, which phosphorylates CREB at Ser133, increasing CREB binding to the VMAT2 promoter and upregulating VMAT2 expression, leading to increased dopamine release and cell survival. This established an ERK/CREB/VMAT2 transcriptional pathway regulating VMAT2.","method":"SH-SY5Y cell LPLI treatment; ERK/CREB phosphorylation (Western blot); chromatin immunoprecipitation (CREB binding to VMAT2 promoter); VMAT2 expression and dopamine release assays; cell viability","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for promoter binding plus pathway inhibitor experiments, single lab, cell line system","pmids":["28627368"],"is_preprint":false},{"year":2011,"finding":"In Rho GTPase inhibition experiments in MN9D dopaminergic cells, inhibition of Rho (via C3 transferase or db-cAMP) decreased α-synuclein mRNA/protein via reduction of nuclear SRF and cytosolic retention of MKL-1, and concomitantly increased VMAT2 and SNARE proteins, demonstrating that Rho GTPase signaling inversely regulates α-synuclein and VMAT2 expression.","method":"MN9D cell treatment with Rho inhibitor C3 transferase and db-cAMP; Western blot and RT-PCR for α-synuclein and VMAT2; nuclear/cytosolic fractionation for SRF/MKL-1; siRNA knockdown of SRF","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple pharmacological and siRNA approaches, single lab, cell line system","pmids":["21699982"],"is_preprint":false},{"year":2008,"finding":"VMAT2 expression in pancreatic β-cells is co-localized with insulin in beta cells (but not in glucagon or somatostatin cells) in human and monkey pancreas; additionally, VMAT2 is expressed in some pancreatic polypeptide (PP) cells, particularly in the pancreatic head (~44–53% co-staining), limiting VMAT2's utility as a specific β-cell marker for PET imaging.","method":"Double-label immunofluorescence with antibodies to VMAT2, insulin, and PP; confocal microscopy of human pancreas subregions","journal":"Journal of molecular histology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — systematic immunofluorescence co-localization with quantification, single lab","pmids":["18791800"],"is_preprint":false},{"year":2002,"finding":"Lithium ions (at therapeutic concentrations, ~1 mM) increase overall VMAT2 mRNA in rat brain (by ~199%), with region-specific differences: 50–100% increases in raphe nuclei, VTA, and substantia nigra, but ~50% decreases in locus coeruleus, suggesting VMAT2 expression is differentially regulated by lithium in distinct monoaminergic neuron populations.","method":"Dietary lithium supplementation in rats; Northern blot; in situ hybridization","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — in vivo pharmacological manipulation with regional mRNA quantification, single lab, two methods","pmids":["12384252"],"is_preprint":false},{"year":2010,"finding":"VMAT2 mRNA and protein are upregulated in rat adrenal chromaffin cells in response to repeated immobilization stress, and VMAT2 expression extends to PNMT-positive (epinephrine-synthesizing) chromaffin cells that normally do not express VMAT2, indicating stress-triggered adaptive expansion of VMAT2 expression to enhance catecholamine storage capacity.","method":"Rat immobilization stress model; Northern blot and RT-PCR for VMAT2 mRNA; immunofluorescence co-localization with TH and PNMT; Western blot","journal":"Cellular and molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — in vivo stress model with immunofluorescence and mRNA analysis, single lab, multiple methods","pmids":["21046458"],"is_preprint":false},{"year":2013,"finding":"A new fluorescent VMAT2 substrate (FFN206) with apparent Km of 1.16 µM (similar to dopamine) localizes to VMAT2-expressing acidic compartments in intact cells and enables quantitative, high-throughput measurement of VMAT2 activity in VMAT2-transfected HEK cells (Z'-factor 0.7–0.8), validating VMAT2's substrate-binding and transport properties in a cell-based system.","method":"Fluorescent substrate synthesis; fluorescence microscopy; microplate reader assays; Km determination; VMAT2-transfected HEK cell assays","journal":"ACS chemical biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with defined substrate kinetics, cell-based validation, single lab","pmids":["23859623"],"is_preprint":false},{"year":2005,"finding":"SLC18A2 promoter haplotypes show differential activity in vitro (~20% difference between two frequent haplotypes), and haplotypes containing -14234G and -2504C are associated with protection against alcoholism, identifying functional promoter variants that regulate VMAT2 transcription.","method":"Re-sequencing of 17.4 kb SLC18A2 promoter region; in vitro promoter activity assays; genotyping of hdSNPs; case-control association analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 1–3 / Moderate — in vitro promoter assay supported by genetic association, single lab","pmids":["15829504"],"is_preprint":false},{"year":2009,"finding":"SLC18A2 is silenced in prostate cancer by DNA hypermethylation (in 88% of tumor samples) and allelic loss (LOH in 23%), and treatment with DNA methylation and HDAC inhibitors rescues VMAT2 expression in three prostate cancer cell lines, identifying epigenetic silencing as a mechanism of SLC18A2 inactivation.","method":"Bisulfite sequencing; expression and SNP microarrays; tissue microarray IHC; methylation and HDAC inhibitor rescue in cancer cell lines","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bisulfite sequencing with pharmacological rescue, multiple cell lines, single lab","pmids":["19228741"],"is_preprint":false},{"year":2002,"finding":"Region-specific targeting of VMAT2 to somatodendritic tubulovesicles in VTA neurons was demonstrated by electron microscopic immunocytochemistry. In paranigral VTA, a higher percentage of VMAT2-labeled dendrites co-express D2 receptors compared to parabrachial VTA, while parabrachial VTA dendrites contain more VMAT2 immunogold deposits per cell, providing a cellular basis for regional heterogeneity in dopamine autoregulation.","method":"Electron microscopic immunocytochemistry with dual labeling for VMAT2 and D2R in VTA subdivisions","journal":"Synapse (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EM-level subcellular localization with quantitative comparison, single lab","pmids":["12112404"],"is_preprint":false},{"year":2019,"finding":"A novel homozygous missense variant p.P316A in SLC18A2 causes brain monoamine vesicular transport disease with absent serotonin in platelet dense granules (demonstrated by electron microscopy and functional platelet aggregation assays), confirming that VMAT2 is required for serotonin storage in platelet dense granules as well as in brain synaptic vesicles.","method":"Whole genome sequencing; Sanger sequencing; platelet electron microscopy; platelet aggregation and ATP secretion assays","journal":"JIMD reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — human genetic variant with direct platelet functional readout (electron microscopy, aggregation assay), single case but direct mechanistic link","pmids":["31240161"],"is_preprint":false},{"year":2008,"finding":"PACAP38 treatment increases VMAT2 expression and function in mouse striatum (at 28 days post-treatment), and genetic reduction of VMAT2 increases methamphetamine neurotoxicity, establishing that PACAP38 neuroprotection against METH is mediated at least partly by upregulating VMAT2 expression.","method":"Systemic PACAP38 administration in mice; VMAT2 expression assays; methamphetamine neurotoxicity challenge (striatal dopamine, GFAP, GLUT5); VMAT2 heterozygous KO comparison","journal":"Neuropeptides","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, indirect inference that VMAT2 increase mediates neuroprotection based on gene expression without direct mechanistic confirmation","pmids":["18533255"],"is_preprint":false}],"current_model":"VMAT2 (SLC18A2) is a vesicular transporter that uses the proton electrochemical gradient across the synaptic vesicle membrane to package dopamine, serotonin, norepinephrine, histamine, and related monoamines (as well as the neurotoxin MPP+ and the reactive metabolite aminochrome) from the neuronal cytoplasm into secretory vesicles; its activity is regulated post-translationally by PKC-mediated phosphorylation of N-terminal Ser15/Ser18 (controlling methamphetamine-stimulated efflux), an intralumenal Cys126–Cys333 disulfide bond (required for efficient transport), JNK3-mediated inhibition (linking microtubule integrity to vesicular DA storage), and G-protein-dependent feedback (Gαo2 in neurons, Gαq in platelets) whereby vesicle filling triggers down-regulation of further uptake; transcription of SLC18A2 is driven by ERK/CREB signaling and is regulated by Rho GTPase/SRF pathways and lithium, and the gene is epigenetically silenced by DNA methylation in prostate cancer; in pancreatic β-cells VMAT2 sequesters dopamine to limit monoamine oxidase-generated ROS, protecting cells from oxidative stress; the Vps35 retromer complex controls retrograde trafficking of VMAT2 to maintain its protein stability; and loss of VMAT2 function—whether by genetic knockout, toxin inhibition, or disease-associated reduction—leads to elevated cytosolic monoamines, oxidative damage, and progressive catecholaminergic neurodegeneration."},"narrative":{"mechanistic_narrative":"SLC18A2 (VMAT2) is a vesicular transporter that packages cytoplasmic monoamines—dopamine, serotonin, noradrenaline, and histamine—into synaptic vesicles and secretory granules, and this sequestration is central to both neurotransmitter storage and protection of monoaminergic cells from cytotoxic insult [PMID:9275230, PMID:34403568, PMID:23859623]. VMAT2 also transports the dopaminergic neurotoxin MPP+ and the reactive dopamine metabolite aminochrome, and the level of VMAT2 sets the size of the releasable vesicular and cytosolic monoamine pools, bidirectionally determining vulnerability to toxins: reduced VMAT2 exacerbates MPTP toxicity while overexpression confers protection [PMID:9275230, PMID:12716422, PMID:27287315, PMID:22483869]. Transport is supported by an intralumenal Cys126–Cys333 disulfide bond required for efficient monoamine uptake [PMID:12009896]. VMAT2 activity is tuned post-translationally: PKC phosphorylation of the N-terminal Ser15/Ser18 controls monoamine sequestration and methamphetamine-stimulated efflux [PMID:24321511]; JNK3 inhibits VMAT2 downstream of microtubule destabilization, linking cytoskeletal integrity to vesicular storage [PMID:25496994]; and vesicle filling triggers heterotrimeric G-protein feedback that down-regulates further uptake (Gαo2 in serotonergic neurons, Gαq in platelets) [PMID:10704487, PMID:12604601]. VMAT2 protein stability is maintained by retromer-dependent retrograde trafficking through interaction with Vps35 [PMID:27924069], and its expression is driven transcriptionally by an ERK/CREB pathway [PMID:28627368]. Beyond the nervous system, VMAT2 in pancreatic β-cells sequesters dopamine to limit monoamine-oxidase-generated ROS and preserve β-cell function [PMID:32826296], and is required for serotonin storage in platelet dense granules [PMID:31240161]. Genetic loss in mice produces progressive multi-system catecholaminergic neurodegeneration with α-synuclein accumulation, and a homozygous p.P316A missense variant causes brain monoamine vesicular transport disease in humans [PMID:21403896, PMID:31240161].","teleology":[{"year":1994,"claim":"Establishing which cells store monoamines vesicularly required distinguishing VMAT2 from VMAT1; isoform-specific antibodies showed VMAT2 is the neuronal/sympathetic transporter while VMAT1 is endocrine, defining cell-type-specific monoamine storage.","evidence":"Isoform-specific antipeptide antibodies and immunohistochemistry on rat tissues and programmed fibroblasts","pmids":["7654518"],"confidence":"High","gaps":["Did not establish transport mechanism or kinetics","Did not resolve subcellular vesicle targeting"]},{"year":1997,"claim":"Whether vesicular sequestration is neuroprotective and behaviorally relevant was unknown; heterozygous knockout mice with halved VMAT2 showed enhanced amphetamine responses and greater MPTP-induced dopamine cell loss, establishing VMAT2 dosage as a determinant of neuroprotection and psychostimulant effects.","evidence":"VMAT2 knockout mouse with behavioral assays and MPTP neurotoxicity cell counting","pmids":["9275230"],"confidence":"High","gaps":["Did not define the post-translational regulators of VMAT2 activity","Mechanism of MPP+ handling not biochemically resolved here"]},{"year":2000,"claim":"How vesicle filling is sensed and fed back to the transporter was unknown; Gαo2 (not Gαo1) was shown to down-regulate VMAT2 in serotonergic cells and to co-localize with VMAT2 on small synaptic vesicles, revealing G-protein-mediated autoregulation.","evidence":"Transport assays with pertussis toxin, EM co-localization, and synaptic vesicle uptake in serotonergic cells/neurons","pmids":["10704487"],"confidence":"High","gaps":["Signal coupling vesicle content to Gαo2 activation not defined","No structural basis for the regulatory interaction"]},{"year":2002,"claim":"The structural features needed for efficient transport were unclear; a lumenal Cys126–Cys333 disulfide bond was identified, and cysteine-to-serine mutation reduced serotonin transport, defining a covalent structural requirement.","evidence":"Thrombin-cleavage mapping, non-reducing SDS-PAGE, site-directed mutagenesis, and [3H]serotonin transport assays","pmids":["12009896"],"confidence":"High","gaps":["No full structural model","How the disulfide affects substrate translocation mechanically unresolved"]},{"year":2003,"claim":"Whether autoregulation is conserved beyond neurons and which G-protein operates in platelets was open; vesicle filling with serotonin/noradrenaline triggered Gαq-mediated down-regulation, confirmed in Gαq knockout platelets, generalizing content-dependent feedback control.","evidence":"Permeabilized platelet transport assays, Tph1 and Gαq knockout reconstitution, GTP-analog activation","pmids":["12604601"],"confidence":"High","gaps":["Molecular sensor coupling vesicle content to Gαq unknown","Direct VMAT2–Gαq contact not demonstrated"]},{"year":2003,"claim":"Whether VMAT2 level sets the size of releasable dopamine pools was untested; mice with ~95% reduced VMAT2 had diminished vesicular DA stores, lower release, reduced amphetamine-evoked efflux, and autoreceptor supersensitivity.","evidence":"Fast cyclic voltammetry in striatal slices with pharmacological dissection in VMAT2-mutant mice","pmids":["12716422"],"confidence":"High","gaps":["Did not address long-term neurodegenerative consequences","Cytosolic monoamine toxicity not directly measured"]},{"year":2005,"claim":"Whether transporter targeting could be enhanced was explored; synaptophysin co-overexpression synergistically increased VMAT2-mediated protection against MPP+, implicating vesicle biogenesis partners in VMAT2 function.","evidence":"Stable co-overexpression of VMAT2 and synaptophysin in MN9D cells with MPP+ viability assays","pmids":["16023584"],"confidence":"Medium","gaps":["No direct measurement of VMAT2 vesicle targeting","Overexpression cell-line context only"]},{"year":2005,"claim":"Functional genetic variation regulating VMAT2 transcription was uncharacterized; promoter haplotypes differing ~20% in activity were linked to protection against alcoholism, identifying regulatory variants.","evidence":"Promoter resequencing, in vitro promoter activity assays, and case-control association","pmids":["15829504"],"confidence":"Medium","gaps":["Causal transcription factor binding the variant sites not defined","Association not mechanistically tied to monoamine phenotype"]},{"year":2007,"claim":"A mechanism for age-related decline of vesicular uptake was lacking; aging rat VMAT2 was shown to deglycosylate and redistribute from vesicle to soluble fractions without total protein loss, suggesting post-translational decline.","evidence":"Subcellular fractionation and Western blot in young vs aged rat striatum","pmids":["17582657"],"confidence":"Medium","gaps":["No direct activity assay confirming functional decline","Enzymes mediating deglycosylation unidentified"]},{"year":2007,"claim":"Whether VMAT2 reciprocally controls plasma-membrane uptake was unknown; deletion or inhibition of VMAT2 reduced DAT activity without TH cell loss, establishing VMAT2 activity as required to maintain DAT function.","evidence":"Primary mesencephalic cultures from VMAT2 KO mice with reserpine pharmacology and DAT activity assays","pmids":["17664021"],"confidence":"Medium","gaps":["Molecular basis of VMAT2–DAT coupling not defined","Single-lab cell-culture readout"]},{"year":2011,"claim":"Whether disrupted vesicular storage alone causes Parkinsonian neurodegeneration was untested; ~95% VMAT2-deficient mice developed progressive catecholamine neuron loss with α-synuclein accumulation and multi-system deficits.","evidence":"Conditional VMAT2-deficient mouse with stereology, immunohistochemistry, and behavioral battery","pmids":["21403896"],"confidence":"High","gaps":["Causal chain from cytosolic monoamines to α-synuclein aggregation not fully resolved","Human disease relevance shown only later"]},{"year":2011,"claim":"Transcriptional coupling of VMAT2 to disease-associated genes was unclear; Rho GTPase inhibition reciprocally increased VMAT2 and decreased α-synuclein via SRF/MKL-1, linking Rho signaling to VMAT2 expression.","evidence":"Rho inhibitor and db-cAMP treatment with fractionation and SRF siRNA in MN9D cells","pmids":["21699982"],"confidence":"Medium","gaps":["Direct transcription factor binding to the VMAT2 promoter not shown here","Cell-line context only"]},{"year":2012,"claim":"Whether VMAT2 protects against endogenous reactive dopamine metabolites was open; VMAT2 overexpression protected nigral cells against aminochrome and vesicles transported [3H]-aminochrome, identifying aminochrome as a VMAT2 substrate.","evidence":"VMAT2-GFP overexpression and [3H]-aminochrome/dopamine vesicle uptake with inhibitor profiling","pmids":["22483869"],"confidence":"Medium","gaps":["Aminochrome uptake inhibited by lobeline but not reserpine, raising unresolved transport-mode questions","Single-lab system"]},{"year":2013,"claim":"The contribution of the N-terminus to drug-evoked efflux was unknown; PKC phosphorylation of Ser15/Ser18 was shown to control monoamine sequestration and to be required for methamphetamine-stimulated efflux.","evidence":"N-terminal truncations, in vitro PKC assay, phospho-mimetic/null mutagenesis, and sequestration/efflux assays in transfected cells","pmids":["24321511"],"confidence":"High","gaps":["In vivo relevance of Ser15/Ser18 phosphorylation not established","Conformational mechanism of efflux not resolved"]},{"year":2013,"claim":"A quantitative cell-based readout of VMAT2 transport was needed; the fluorescent substrate FFN206 (Km ~1.16 µM) localized to VMAT2 acidic compartments and enabled high-throughput activity measurement, validating substrate-binding properties.","evidence":"Fluorescent substrate synthesis, microscopy, and microplate assays in VMAT2-transfected HEK cells","pmids":["23859623"],"confidence":"Medium","gaps":["Does not address physiological regulation","Heterologous cell system only"]},{"year":2013,"claim":"Whether VMAT2-controlled monoamines influence endocrine differentiation was unknown; VMAT2 inhibition promoted β-cell differentiation from progenitors and yielded transplantable insulin-producing cells, implicating monoamines as negative regulators of β-cell fate.","evidence":"Chemical screen with VMAT2 inhibitors in ES-cell differentiation and diabetic mouse transplantation","pmids":["24316738"],"confidence":"High","gaps":["Direct monoamine signaling pathway in progenitors not fully mapped","Pharmacological inhibitors may have off-target effects"]},{"year":2016,"claim":"How VMAT2 protein stability is maintained was unknown; VMAT2 was shown to undergo retromer-dependent retrograde trafficking via Vps35 interaction, with Vps35 knockdown reducing VMAT2 half-life.","evidence":"Co-immunoprecipitation, localization imaging, Vps35 siRNA, and VMAT2 half-life measurement in non-neuronal cells","pmids":["27924069"],"confidence":"Medium","gaps":["Single Co-IP without neuronal validation","Degradation route of mislocalized VMAT2 not defined"]},{"year":2016,"claim":"Whether VMAT2 dosage bidirectionally sets toxin vulnerability was tested; on identical genetic background, VMAT2-LO mice showed exacerbated MPTP toxicity and progressive terminal loss while VMAT2-HI mice were protected.","evidence":"VMAT2-LO and VMAT2-HI transgenic mice with vesicular uptake assays and MPTP challenge","pmids":["27287315"],"confidence":"High","gaps":["Did not resolve the molecular event triggering terminal degeneration","Human relevance inferred indirectly"]},{"year":2017,"claim":"A transcriptional pathway upregulating VMAT2 for neuroprotection was undefined; ERK-driven CREB phosphorylation increased CREB binding to the VMAT2 promoter and VMAT2 expression, protecting against MPP+.","evidence":"ERK/CREB phosphorylation, ChIP of CREB at the VMAT2 promoter, and viability assays in SH-SY5Y cells","pmids":["28627368"],"confidence":"Medium","gaps":["In vivo validation lacking","Cell-line and laser-stimulus-specific context"]},{"year":2019,"claim":"Whether VMAT2 loss causes human disease and platelet storage failure was open; a homozygous p.P316A variant caused brain monoamine vesicular transport disease with absent serotonin in platelet dense granules.","evidence":"Whole genome sequencing with platelet electron microscopy and aggregation/secretion assays","pmids":["31240161"],"confidence":"Medium","gaps":["Single case","Structural impact of P316A on transport not directly assayed"]},{"year":2020,"claim":"The protective role of VMAT2 in β-cells was unproven; β-cell-specific Vmat2 knockout elevated ROS and accelerated β-cell dysfunction under high-fat diet, showing VMAT2 sequesters dopamine to limit MAO-generated oxidative stress.","evidence":"β-cell-specific conditional KO mice with glucose/insulin tolerance tests, ROS measurement, and β-cell marker immunostaining","pmids":["32826296"],"confidence":"High","gaps":["Quantitative contribution of MAO-derived ROS vs other sources not isolated","Human β-cell relevance not established"]},{"year":2021,"claim":"Whether VMAT2 controls monoamine turnover and brain development was tested; zebrafish Vmat2 loss reduced monoamines while raising metabolites and altered Notch1a/Pax2a in proliferative zones, linking VMAT2 to monoamine turnover and developmental gene expression.","evidence":"CRISPR/Cas9 zebrafish knockout with HPLC, qPCR, in situ hybridization, and behavioral assays","pmids":["34403568"],"confidence":"High","gaps":["Mechanism linking monoamine loss to developmental gene changes not defined","Ortholog model may differ from mammalian regulation"]},{"year":null,"claim":"It remains unresolved how the multiple post-translational regulators (PKC/Ser15-18, JNK3, the Cys126–Cys333 disulfide, Gαo2/Gαq feedback) integrate on a single VMAT2 molecule, and what high-resolution structural mechanism couples proton gradient to monoamine translocation.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model integrating regulatory sites","Sensor coupling vesicle content to G-protein feedback unidentified","In vivo interplay of regulators untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,4,7,15,24]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[0,12,24]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[2,14,27]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[0,7,9]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[2,16]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[11,15]}],"complexes":[],"partners":["VPS35","GNAO1","GNAQ","SYP","MAPK10"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q05940","full_name":"Synaptic vesicular amine transporter","aliases":["Solute carrier family 18 member 2","Vesicular amine transporter 2","VAT2","Vesicular monoamine transporter 2"],"length_aa":514,"mass_kda":55.7,"function":"Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. Transports a variety of catecholamines such as dopamine, adrenaline and noradrenaline, histamine, and indolamines such as serotonin (PubMed:23363473, PubMed:37914936, PubMed:38081299, PubMed:38517752, PubMed:8643547). Regulates the transvesicular monoaminergic gradient that determines the quantal size. Mediates somatodendritic dopamine release in hippocampal neurons, likely as part of a regulated secretory pathway that integrates retrograde synaptic signals (By similarity). Acts as a primary transporter for striatal dopamine loading ensuring impulse-dependent release of dopamine at the synaptic cleft (By similarity). Responsible for histamine and serotonin storage and subsequent corelease from mast cell granules (PubMed:8860238)","subcellular_location":"Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane; Cytoplasmic vesicle, secretory vesicle membrane; Cell projection, axon; Cell projection, dendrite","url":"https://www.uniprot.org/uniprotkb/Q05940/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC18A2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SLC18A2","total_profiled":1310},"omim":[{"mim_id":"618049","title":"PARKINSONISM-DYSTONIA 2, INFANTILE-ONSET; PKDYS2","url":"https://www.omim.org/entry/618049"},{"mim_id":"613135","title":"PARKINSONISM-DYSTONIA 1, INFANTILE-ONSET; PKDYS1","url":"https://www.omim.org/entry/613135"},{"mim_id":"602887","title":"DISCS LARGE MAGUK SCAFFOLD PROTEIN 4; DLG4","url":"https://www.omim.org/entry/602887"},{"mim_id":"193002","title":"SOLUTE CARRIER FAMILY 18 (VESICULAR MONOAMINE), MEMBER 1; SLC18A1","url":"https://www.omim.org/entry/193002"},{"mim_id":"193001","title":"SOLUTE CARRIER FAMILY 18 (VESICULAR MONOAMINE), MEMBER 2; SLC18A2","url":"https://www.omim.org/entry/193001"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Centrosome","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":36.4},{"tissue":"cervix","ntpm":28.1}],"url":"https://www.proteinatlas.org/search/SLC18A2"},"hgnc":{"alias_symbol":["SVMT","SVAT","VAT2"],"prev_symbol":["VMAT2"]},"alphafold":{"accession":"Q05940","domains":[{"cath_id":"1.20.1250.20","chopping":"16-52_122-478","consensus_level":"medium","plddt":89.2807,"start":16,"end":478}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q05940","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q05940-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q05940-F1-predicted_aligned_error_v6.png","plddt_mean":77.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC18A2","jax_strain_url":"https://www.jax.org/strain/search?query=SLC18A2"},"sequence":{"accession":"Q05940","fasta_url":"https://rest.uniprot.org/uniprotkb/Q05940.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q05940/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q05940"}},"corpus_meta":[{"pmid":"9275230","id":"PMC_9275230","title":"VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9275230","citation_count":314,"is_preprint":false},{"pmid":"7654518","id":"PMC_7654518","title":"Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat.","date":"1994","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/7654518","citation_count":193,"is_preprint":false},{"pmid":"10192785","id":"PMC_10192785","title":"Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.","date":"1999","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10192785","citation_count":162,"is_preprint":false},{"pmid":"16741673","id":"PMC_16741673","title":"Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression.","date":"2006","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/16741673","citation_count":136,"is_preprint":false},{"pmid":"21272013","id":"PMC_21272013","title":"VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.","date":"2011","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21272013","citation_count":130,"is_preprint":false},{"pmid":"24305809","id":"PMC_24305809","title":"Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24305809","citation_count":107,"is_preprint":false},{"pmid":"12871984","id":"PMC_12871984","title":"Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors.","date":"2003","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/12871984","citation_count":105,"is_preprint":false},{"pmid":"17988241","id":"PMC_17988241","title":"VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17988241","citation_count":96,"is_preprint":false},{"pmid":"21403896","id":"PMC_21403896","title":"VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.","date":"2011","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/21403896","citation_count":89,"is_preprint":false},{"pmid":"24937131","id":"PMC_24937131","title":"The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24937131","citation_count":88,"is_preprint":false},{"pmid":"15135235","id":"PMC_15135235","title":"Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and normotensive pregnancies.","date":"2004","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/15135235","citation_count":86,"is_preprint":false},{"pmid":"18791800","id":"PMC_18791800","title":"Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas.","date":"2008","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/18791800","citation_count":79,"is_preprint":false},{"pmid":"31303260","id":"PMC_31303260","title":"Which Dopamine Polymorphisms Are Functional? Systematic Review and Meta-analysis of COMT, DAT, DBH, DDC, DRD1-5, MAOA, MAOB, TH, VMAT1, and VMAT2.","date":"2019","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/31303260","citation_count":71,"is_preprint":false},{"pmid":"12505801","id":"PMC_12505801","title":"Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users.","date":"2003","source":"The American journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12505801","citation_count":65,"is_preprint":false},{"pmid":"18522241","id":"PMC_18522241","title":"GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys.","date":"2008","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/18522241","citation_count":63,"is_preprint":false},{"pmid":"23185343","id":"PMC_23185343","title":"Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23185343","citation_count":62,"is_preprint":false},{"pmid":"18533255","id":"PMC_18533255","title":"PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.","date":"2008","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/18533255","citation_count":56,"is_preprint":false},{"pmid":"10704487","id":"PMC_10704487","title":"The neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go(2).","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10704487","citation_count":56,"is_preprint":false},{"pmid":"23859623","id":"PMC_23859623","title":"New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2).","date":"2013","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/23859623","citation_count":55,"is_preprint":false},{"pmid":"12716422","id":"PMC_12716422","title":"Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.","date":"2003","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12716422","citation_count":54,"is_preprint":false},{"pmid":"17425337","id":"PMC_17425337","title":"Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigra-derived cell line--an experimental cell model for dopamine toxicity studies.","date":"2007","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/17425337","citation_count":53,"is_preprint":false},{"pmid":"24316738","id":"PMC_24316738","title":"VMAT2 identified as a regulator of late-stage β-cell differentiation.","date":"2013","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/24316738","citation_count":51,"is_preprint":false},{"pmid":"12710012","id":"PMC_12710012","title":"VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.","date":"2003","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12710012","citation_count":51,"is_preprint":false},{"pmid":"11099463","id":"PMC_11099463","title":"The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins.","date":"2000","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/11099463","citation_count":49,"is_preprint":false},{"pmid":"12604601","id":"PMC_12604601","title":"The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12604601","citation_count":49,"is_preprint":false},{"pmid":"12655306","id":"PMC_12655306","title":"Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice.","date":"2002","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12655306","citation_count":47,"is_preprint":false},{"pmid":"24018103","id":"PMC_24018103","title":"Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.","date":"2013","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/24018103","citation_count":45,"is_preprint":false},{"pmid":"15829504","id":"PMC_15829504","title":"SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15829504","citation_count":42,"is_preprint":false},{"pmid":"27287315","id":"PMC_27287315","title":"Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.","date":"2016","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27287315","citation_count":42,"is_preprint":false},{"pmid":"12112404","id":"PMC_12112404","title":"Region-specific targeting of dopamine D2-receptors and somatodendritic vesicular monoamine transporter 2 (VMAT2) within ventral tegmental area subdivisions.","date":"2002","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12112404","citation_count":40,"is_preprint":false},{"pmid":"22483869","id":"PMC_22483869","title":"Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22483869","citation_count":38,"is_preprint":false},{"pmid":"19798748","id":"PMC_19798748","title":"Enzymatic-nonenzymatic cellular antioxidant defense systems response and immunohistochemical detection of MDMA, VMAT2, HSP70, and apoptosis as biomarkers for MDMA (Ecstasy) neurotoxicity.","date":"2010","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/19798748","citation_count":38,"is_preprint":false},{"pmid":"15988470","id":"PMC_15988470","title":"Association of DNA polymorphisms in the synaptic vesicular amine transporter gene (SLC18A2) with alcohol and nicotine dependence.","date":"2005","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15988470","citation_count":37,"is_preprint":false},{"pmid":"21699982","id":"PMC_21699982","title":"Rho GTPase regulation of α-synuclein and VMAT2: implications for pathogenesis of Parkinson's disease.","date":"2011","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/21699982","citation_count":37,"is_preprint":false},{"pmid":"16023584","id":"PMC_16023584","title":"Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells.","date":"2005","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/16023584","citation_count":36,"is_preprint":false},{"pmid":"18834437","id":"PMC_18834437","title":"VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease.","date":"2008","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18834437","citation_count":35,"is_preprint":false},{"pmid":"9733951","id":"PMC_9733951","title":"Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system.","date":"1998","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9733951","citation_count":35,"is_preprint":false},{"pmid":"22193525","id":"PMC_22193525","title":"In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.","date":"2011","source":"The American journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22193525","citation_count":34,"is_preprint":false},{"pmid":"29433808","id":"PMC_29433808","title":"VMAT2 inhibitors for the treatment of tardive dyskinesia.","date":"2018","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29433808","citation_count":31,"is_preprint":false},{"pmid":"23978383","id":"PMC_23978383","title":"Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.","date":"2013","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23978383","citation_count":31,"is_preprint":false},{"pmid":"21742018","id":"PMC_21742018","title":"Co-expression studies of the orphan carrier protein Slc10a4 and the vesicular carriers VAChT and VMAT2 in the rat central and peripheral nervous system.","date":"2011","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21742018","citation_count":31,"is_preprint":false},{"pmid":"22532702","id":"PMC_22532702","title":"Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition.","date":"2012","source":"Schizophrenia bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/22532702","citation_count":31,"is_preprint":false},{"pmid":"16116033","id":"PMC_16116033","title":"Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis.","date":"2005","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/16116033","citation_count":30,"is_preprint":false},{"pmid":"23221614","id":"PMC_23221614","title":"Vesicular monoamine transporter, type 2 (VMAT2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas.","date":"2012","source":"Islets","url":"https://pubmed.ncbi.nlm.nih.gov/23221614","citation_count":30,"is_preprint":false},{"pmid":"21046458","id":"PMC_21046458","title":"Vesicular monoamine transporters (VMATs) in adrenal chromaffin cells: stress-triggered induction of VMAT2 and expression in epinephrine synthesizing cells.","date":"2010","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21046458","citation_count":30,"is_preprint":false},{"pmid":"24054151","id":"PMC_24054151","title":"Localization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease.","date":"2013","source":"Advances in pharmacology (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/24054151","citation_count":29,"is_preprint":false},{"pmid":"23404442","id":"PMC_23404442","title":"Species-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models.","date":"2013","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/23404442","citation_count":28,"is_preprint":false},{"pmid":"22359591","id":"PMC_22359591","title":"No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22359591","citation_count":28,"is_preprint":false},{"pmid":"22407500","id":"PMC_22407500","title":"The effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2.","date":"2012","source":"Neurotoxicity research","url":"https://pubmed.ncbi.nlm.nih.gov/22407500","citation_count":27,"is_preprint":false},{"pmid":"29680151","id":"PMC_29680151","title":"VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine).","date":"2018","source":"Progress in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29680151","citation_count":25,"is_preprint":false},{"pmid":"34403568","id":"PMC_34403568","title":"Vesicular monoamine transporter 2 (SLC18A2) regulates monoamine turnover and brain development in zebrafish.","date":"2021","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34403568","citation_count":25,"is_preprint":false},{"pmid":"17582657","id":"PMC_17582657","title":"Deglycosylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging.","date":"2007","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/17582657","citation_count":25,"is_preprint":false},{"pmid":"19228741","id":"PMC_19228741","title":"Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19228741","citation_count":24,"is_preprint":false},{"pmid":"27836486","id":"PMC_27836486","title":"Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.","date":"2016","source":"Journal of chemical neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/27836486","citation_count":24,"is_preprint":false},{"pmid":"31240161","id":"PMC_31240161","title":"A novel missense variant in SLC18A2 causes recessive brain monoamine vesicular transport disease and absent serotonin in platelets.","date":"2019","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/31240161","citation_count":24,"is_preprint":false},{"pmid":"25496994","id":"PMC_25496994","title":"JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death.","date":"2014","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/25496994","citation_count":23,"is_preprint":false},{"pmid":"28627368","id":"PMC_28627368","title":"Photoactivation of ERK/CREB/VMAT2 pathway attenuates MPP+-induced neuronal injury in a cellular model of Parkinson's disease.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/28627368","citation_count":22,"is_preprint":false},{"pmid":"9733958","id":"PMC_9733958","title":"Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. II. Expression in neural crest derivatives and their target sites in the rat.","date":"1998","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9733958","citation_count":22,"is_preprint":false},{"pmid":"29468404","id":"PMC_29468404","title":"Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes.","date":"2018","source":"Molecular imaging and biology","url":"https://pubmed.ncbi.nlm.nih.gov/29468404","citation_count":22,"is_preprint":false},{"pmid":"12384252","id":"PMC_12384252","title":"Lithium ions modulate the expression of VMAT2 in rat brain.","date":"2002","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/12384252","citation_count":21,"is_preprint":false},{"pmid":"12009896","id":"PMC_12009896","title":"Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12009896","citation_count":21,"is_preprint":false},{"pmid":"29721633","id":"PMC_29721633","title":"Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging.","date":"2018","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/29721633","citation_count":20,"is_preprint":false},{"pmid":"11702019","id":"PMC_11702019","title":"Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs.","date":"2001","source":"Neuropsychobiology","url":"https://pubmed.ncbi.nlm.nih.gov/11702019","citation_count":19,"is_preprint":false},{"pmid":"18041582","id":"PMC_18041582","title":"A metabolomic study of brain tissues from aged mice with low expression of the vesicular monoamine transporter 2 (VMAT2) gene.","date":"2007","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/18041582","citation_count":19,"is_preprint":false},{"pmid":"23867769","id":"PMC_23867769","title":"The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.","date":"2013","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23867769","citation_count":19,"is_preprint":false},{"pmid":"10521591","id":"PMC_10521591","title":"Heterozygous VMAT2 knockout mice display prolonged QT intervals: possible contributions to sudden death.","date":"1999","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10521591","citation_count":18,"is_preprint":false},{"pmid":"20181938","id":"PMC_20181938","title":"High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.","date":"2010","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20181938","citation_count":17,"is_preprint":false},{"pmid":"23504072","id":"PMC_23504072","title":"Association of VMAT2 gene polymorphisms with alcohol dependence.","date":"2013","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/23504072","citation_count":17,"is_preprint":false},{"pmid":"20805303","id":"PMC_20805303","title":"The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.","date":"2010","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20805303","citation_count":17,"is_preprint":false},{"pmid":"32826296","id":"PMC_32826296","title":"VMAT2 Safeguards β-Cells Against Dopamine Cytotoxicity Under High-Fat Diet-Induced Stress.","date":"2020","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/32826296","citation_count":16,"is_preprint":false},{"pmid":"28560316","id":"PMC_28560316","title":"VMAT2-Mediated Neurotransmission from Midbrain Leptin Receptor Neurons in Feeding Regulation.","date":"2017","source":"eNeuro","url":"https://pubmed.ncbi.nlm.nih.gov/28560316","citation_count":16,"is_preprint":false},{"pmid":"27673755","id":"PMC_27673755","title":"Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18F-FP-DTBZ in baboons.","date":"2016","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/27673755","citation_count":16,"is_preprint":false},{"pmid":"38497033","id":"PMC_38497033","title":"Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.","date":"2024","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38497033","citation_count":15,"is_preprint":false},{"pmid":"12428733","id":"PMC_12428733","title":"L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice.","date":"2002","source":"Neurotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/12428733","citation_count":15,"is_preprint":false},{"pmid":"27764160","id":"PMC_27764160","title":"CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27764160","citation_count":15,"is_preprint":false},{"pmid":"11443533","id":"PMC_11443533","title":"Exon/intron boundaries, novel polymorphisms, and association analysis with schizophrenia of the human synaptic vesicle monoamine transporter (SVMT) gene.","date":"2001","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/11443533","citation_count":14,"is_preprint":false},{"pmid":"17427184","id":"PMC_17427184","title":"Identification of two risk haplotypes for schizophrenia and bipolar disorder in the synaptic vesicle monoamine transporter gene (SVMT).","date":"2007","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17427184","citation_count":14,"is_preprint":false},{"pmid":"34758845","id":"PMC_34758845","title":"VMAT2 availability in Parkinson's disease with probable REM sleep behaviour disorder.","date":"2021","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/34758845","citation_count":14,"is_preprint":false},{"pmid":"24321511","id":"PMC_24321511","title":"N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.","date":"2013","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24321511","citation_count":14,"is_preprint":false},{"pmid":"38885579","id":"PMC_38885579","title":"Gastrodin relieves Parkinson's disease-related motor deficits by facilitating the MEK-dependent VMAT2 to maintain dopamine homeostasis.","date":"2024","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38885579","citation_count":13,"is_preprint":false},{"pmid":"30697146","id":"PMC_30697146","title":"Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent.","date":"2019","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30697146","citation_count":13,"is_preprint":false},{"pmid":"15150286","id":"PMC_15150286","title":"The vesicular monoamine transporter 2 (VMAT2) is expressed by normal and tumor cutaneous mast cells and Langerhans cells of the skin but is absent from Langerhans cell histiocytosis.","date":"2004","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/15150286","citation_count":13,"is_preprint":false},{"pmid":"19835933","id":"PMC_19835933","title":"Increased expression of VMAT2 in dopaminergic neurons during nicotine withdrawal.","date":"2009","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/19835933","citation_count":13,"is_preprint":false},{"pmid":"29557243","id":"PMC_29557243","title":"Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.","date":"2018","source":"Expert review of neurotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29557243","citation_count":13,"is_preprint":false},{"pmid":"17664021","id":"PMC_17664021","title":"Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.","date":"2007","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/17664021","citation_count":13,"is_preprint":false},{"pmid":"38498979","id":"PMC_38498979","title":"N-acetylcysteine increases dopamine release and prevents the deleterious effects of 6-OHDA on the expression of VMAT2, α-synuclein, and tyrosine hydroxylase.","date":"2024","source":"Neurological research","url":"https://pubmed.ncbi.nlm.nih.gov/38498979","citation_count":12,"is_preprint":false},{"pmid":"26956479","id":"PMC_26956479","title":"Deficits in coordinated motor behavior and in nigrostriatal dopaminergic system ameliorated and VMAT2 expression up-regulated in aged male rats by administration of testosterone propionate.","date":"2016","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/26956479","citation_count":12,"is_preprint":false},{"pmid":"21982574","id":"PMC_21982574","title":"Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas.","date":"2011","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/21982574","citation_count":12,"is_preprint":false},{"pmid":"30983500","id":"PMC_30983500","title":"VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence.","date":"2019","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/30983500","citation_count":11,"is_preprint":false},{"pmid":"34078222","id":"PMC_34078222","title":"A case report of infantile parkinsonism-dystonia-2 caused by homozygous mutation in the SLC18A2 gene.","date":"2021","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34078222","citation_count":11,"is_preprint":false},{"pmid":"33240055","id":"PMC_33240055","title":"Selective Knockout of the Vesicular Monoamine Transporter 2 (Vmat2) Gene in Calbindin2/Calretinin-Positive Neurons Results in Profound Changes in Behavior and Response to Drugs of Abuse.","date":"2020","source":"Frontiers in behavioral neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33240055","citation_count":11,"is_preprint":false},{"pmid":"28477711","id":"PMC_28477711","title":"Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy.","date":"2017","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28477711","citation_count":11,"is_preprint":false},{"pmid":"30954223","id":"PMC_30954223","title":"Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30954223","citation_count":10,"is_preprint":false},{"pmid":"27924069","id":"PMC_27924069","title":"Retrograde trafficking of VMAT2 and its role in protein stability in non-neuronal cells.","date":"2016","source":"Journal of biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/27924069","citation_count":10,"is_preprint":false},{"pmid":"26122704","id":"PMC_26122704","title":"A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.","date":"2015","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26122704","citation_count":10,"is_preprint":false},{"pmid":"32410942","id":"PMC_32410942","title":"Alterations of the Motor and Olfactory Functions Related to Parkinson's Disease in Transgenic Mice With a VMAT2-Deficiency in Dopaminergic Neurons.","date":"2020","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32410942","citation_count":10,"is_preprint":false},{"pmid":"38238580","id":"PMC_38238580","title":"Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis.","date":"2024","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38238580","citation_count":9,"is_preprint":false},{"pmid":"29455579","id":"PMC_29455579","title":"VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.","date":"2018","source":"Journal of pharmacy practice","url":"https://pubmed.ncbi.nlm.nih.gov/29455579","citation_count":8,"is_preprint":false},{"pmid":"17105913","id":"PMC_17105913","title":"Age-dependent effects of methamphetamine on VMAT-2.","date":"2006","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17105913","citation_count":8,"is_preprint":false},{"pmid":"34986152","id":"PMC_34986152","title":"Motility phenotype in a zebrafish vmat2 mutant.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34986152","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54626,"output_tokens":8297,"usd":0.144167,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18170,"output_tokens":6551,"usd":0.127312,"stage2_stop_reason":"end_turn"},"total_usd":0.271479,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"VMAT2 pumps monoamine neurotransmitters and dopaminergic neurotoxins (MPP+) from neuronal cytoplasm into synaptic vesicles. Heterozygous VMAT2 knockout mice (50% VMAT2 levels) show enhanced amphetamine locomotion, diminished conditioned reward, and >2× dopamine cell loss after MPTP, establishing that vesicular sequestration contributes to neuroprotection and modulates amphetamine behavioral effects.\",\n      \"method\": \"VMAT2 knockout mouse generation; behavioral assays (conditioned place preference, locomotion); MPTP neurotoxicity with cell counting\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with multiple orthogonal behavioral and neurochemical readouts, replicated in subsequent studies\",\n      \"pmids\": [\"9275230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"VMAT2 (but not VMAT1) is expressed in neurons of the sympathetic nervous system and aminergic neurons in the enteric and central nervous systems, while VMAT1 is restricted to endocrine/paracrine cells; the two isoforms show mutually exclusive expression in peripheral endocrine cells, establishing cell-type-specific patterns of vesicular monoamine storage.\",\n      \"method\": \"Isoform-specific polyclonal antipeptide antibodies; immunostaining of monkey fibroblasts programmed to express VMAT1 or VMAT2; immunohistochemistry on rat tissues\",\n      \"journal\": \"Journal of molecular neuroscience : MN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — antibody specificity validated by isoform-selective cell expression system; replicated across multiple subsequent studies\",\n      \"pmids\": [\"7654518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"VMAT2 activity in BON serotonergic cells and in serotonergic raphe neurons is down-regulated specifically by the heterotrimeric G-protein Gαo2 (pertussis toxin-sensitive), but not by Gαo1. Electron microscopy showed VMAT2 and Gαo2 co-localizing preferentially on small synaptic vesicles in serotonergic terminals of prefrontal cortex, and Go2-dependent modulation was confirmed in crude synaptic vesicle preparations from this brain area.\",\n      \"method\": \"Transport assays in BON cells and primary raphe neurons; pertussis toxin treatment; electron microscopic immunocytochemistry; synaptic vesicle preparation uptake assays\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro functional assays with pertussis toxin, EM co-localization, and vesicle preparation uptake, multiple cell systems\",\n      \"pmids\": [\"10704487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Vesicular filling of VMAT2-containing platelets with serotonin or noradrenaline triggers Gαq-mediated down-regulation of VMAT2 activity, demonstrating an autoregulatory mechanism whereby vesicle content controls transporter activity. Gαq (not serotonergic/noradrenergic/thromboxane receptors) mediates this effect, shown using Gαq knockout platelets.\",\n      \"method\": \"Streptolysin O-permeabilized platelet transport assays; Tph1−/− (tryptophan hydroxylase knockout) platelet reconstitution; Gαq knockout mouse platelets; GTP analog (GMppNp) activation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution in depleted platelets, genetic KO of Gαq, multiple orthogonal approaches\",\n      \"pmids\": [\"12604601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Human VMAT2 contains an intramolecular disulfide bond between Cys126 (in lumenal loop 1/2) and Cys333 (in lumenal loop 7/8). Mutation of either cysteine to serine reduced [³H]serotonin transport and eliminated the DTT-reversible covalent bond, indicating this disulfide bond contributes to efficient monoamine transport.\",\n      \"method\": \"Engineered thrombin cleavage site in deglycosylated HA-tagged human VMAT2; SDS-PAGE under reducing/non-reducing conditions; site-directed mutagenesis (C126S, C333S); [³H]serotonin transport assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with mutagenesis and functional transport assays, direct structural characterization\",\n      \"pmids\": [\"12009896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The 20-amino-acid N-terminus of VMAT2 regulates monoamine sequestration and methamphetamine-stimulated efflux. PKC phosphorylates the N-terminus at Ser15 and Ser18; phospho-mimetic (S15D/S18D) mutations reduced [³H]-5HT sequestration and abolished methamphetamine-stimulated efflux of pre-loaded substrate, while alanine mutations (S15A/S18A) maintained sequestration but eliminated METH-stimulated efflux.\",\n      \"method\": \"N-terminal truncation constructs; GST-fusion PKC phosphorylation assay; site-directed mutagenesis (S15D, S18D, S15A, S18A); [³H]-5HT sequestration and efflux assays in transfected cells\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis plus functional transport/efflux assays, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"24321511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Rotenone inhibits VMAT2 activity (without reducing VMAT2 protein levels) via JNK3, the neural-specific JNK isoform. Rotenone-induced microtubule destabilization activates JNK, which inhibits VMAT2 activity; pharmacological JNK inhibition (SP600125) or incubation of synaptic vesicles with recombinant JNK3 protein directly inhibited VMAT2 activity, placing JNK3 as a novel upstream regulator of VMAT2.\",\n      \"method\": \"Primary dopamine neuron cultures; JNK isoform-specific knockdown; pharmacological JNK inhibition; in vitro incubation of recombinant JNK3 with purified mesencephalic synaptic vesicles; VMAT2 activity assays\",\n      \"journal\": \"Toxicology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution of JNK3 inhibition of VMAT2 vesicles, supported by pharmacological and genetic inhibition in neurons\",\n      \"pmids\": [\"25496994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"VMAT2 mutant mice with ~95% reduction in VMAT2 expression have reduced vesicular dopamine stores, lower impulse-dependent DA release, reduced amphetamine-evoked DAT-mediated efflux, and compensatory supersensitivity of D2/D3 release-regulating autoreceptors, demonstrating that VMAT2 levels determine the size of releasable vesicular and cytosolic dopamine pools.\",\n      \"method\": \"Fast cyclic voltammetry in striatal slices; pharmacological dissection with GBR12935 (DAT blocker), sulpiride (D2/D3 antagonist), quinpirole (agonist); homozygous VMAT2 mutant mice vs. wild-type\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ex vivo voltammetry with multiple pharmacological probes, genetic model, replicated across conditions\",\n      \"pmids\": [\"12716422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VMAT2 level inversely determines vulnerability to MPTP neurotoxicity: VMAT2-LO mice (95% reduction) show reduced vesicular uptake, progressive dopaminergic terminal loss, and exacerbated MPTP toxicity, while VMAT2-HI (overexpressing) mice are protected from MPTP-induced striatal terminal loss and show altered handling of newly synthesized dopamine.\",\n      \"method\": \"VMAT2-LO and VMAT2-HI transgenic mice on identical C57BL/6 background; vesicular uptake assays; MPTP treatment with neurochemical and immunohistochemical endpoints\",\n      \"journal\": \"Toxicological sciences : an official journal of the Society of Toxicology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — bidirectional genetic manipulation (KO and OE) with direct vesicular uptake assay and toxin challenge, same genetic background\",\n      \"pmids\": [\"27287315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"VMAT2-deficient mice (95% reduction) develop progressive catecholamine neuron loss in the substantia nigra, locus coeruleus, and dorsal raphe, with α-synuclein accumulation, and display progressive motor deficits, olfactory dysfunction, delayed gastric emptying, anxiety, and depression-like phenotype, establishing that disrupted vesicular monoamine storage is sufficient to produce multi-system neurodegeneration resembling Parkinson's disease.\",\n      \"method\": \"Conditional VMAT2-deficient mouse model; immunohistochemistry; behavioral battery; stereological cell counting; α-synuclein staining\",\n      \"journal\": \"Parkinson's disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic model with comprehensive neurochemical and behavioral phenotyping, replicated across multiple labs\",\n      \"pmids\": [\"21403896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"VMAT2 inhibition by reserpine or tetrabenazine promotes late-stage differentiation of Pdx1-positive pancreatic progenitors into Ngn3-positive endocrine precursors and subsequently into β cells. VMAT2-controlled monoamines (dopamine, histamine, serotonin) negatively regulate β-cell differentiation; ES cell-derived β cells produced by this protocol reversed hyperglycemia in diabetic mice upon transplantation.\",\n      \"method\": \"Chemical screening with VMAT2 inhibitors; ES cell differentiation assays; glucose-stimulated insulin secretion; transplantation into AKITA diabetic mice\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional differentiation assay with pharmacological VMAT2 inhibition, in vivo transplantation validation, multiple orthogonal readouts\",\n      \"pmids\": [\"24316738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VMAT2 in pancreatic β-cells sequesters dopamine into vesicles to protect it from monoamine oxidase-mediated degradation, thereby limiting reactive oxygen species (ROS) generation. β-cell-specific Vmat2 knockout mice show elevated insulin secretion under glucose stimulation but, under prolonged high-fat diet, exhibit impaired glucose tolerance, progressive β-cell dysfunction, elevated ROS, accelerated β-cell dedifferentiation and loss.\",\n      \"method\": \"β-cell-specific Vmat2 conditional KO mice; glucose/insulin tolerance tests; ROS measurement; insulin secretion assays; immunostaining for β-cell markers\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific KO with mechanistic ROS assays and functional metabolic phenotyping, multiple orthogonal methods\",\n      \"pmids\": [\"32826296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss of Vmat2 in zebrafish (CRISPR/Cas9 5-bp deletion) reduces dopamine, noradrenaline, serotonin, and histamine levels while increasing monoamine metabolites (elevated turnover), upregulates dopamine-synthesizing enzymes and histidine decarboxylase-expressing neurons, and downregulates Notch1a and Pax2a in brain proliferative zones, demonstrating that Vmat2 controls monoamine turnover and brain developmental gene expression.\",\n      \"method\": \"CRISPR/Cas9 zebrafish knockout; HPLC monoamine quantification; qPCR; in situ hybridization; immunocytochemistry; behavioral assays\",\n      \"journal\": \"Acta physiologica (Oxford, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with multiple orthogonal biochemical and molecular readouts in an ortholog model\",\n      \"pmids\": [\"34403568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"During normal aging in rats, VMAT2 undergoes deglycosylation and subcellular redistribution: the three glycosylation forms (75, 55, 45 kDa) virtually disappear from the synaptic vesicle-enriched fraction while the 55 kDa partially glycosylated form accumulates in the soluble compartment, without changes in total VMAT2 protein or mRNA, providing a mechanism for age-related decline of vesicular monoamine uptake.\",\n      \"method\": \"Subcellular fractionation of rat striatum (synaptosomal membrane and synaptic vesicle fractions); Western blot; in situ hybridization for VMAT2 mRNA; comparison of young vs. aged rats\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — fractionation with functional link to VMAT2 activity decline, single lab, biochemical readout without direct activity confirmation\",\n      \"pmids\": [\"17582657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Synaptophysin enhances VMAT2-mediated neuroprotection against MPP+ toxicity in MN9D dopaminergic cells. Co-overexpression of VMAT2 and synaptophysin produced synergistic protection, suggesting synaptophysin promotes biogenesis of secretory vesicles and influences VMAT2 targeting to these vesicles.\",\n      \"method\": \"Stable overexpression of VMAT2 and/or synaptophysin in MN9D cells; MPP+ toxicity assays; cell viability measurements\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — overexpression in cell line with viability assay, single lab, no direct vesicle targeting measurement\",\n      \"pmids\": [\"16023584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Overexpression of VMAT2 (7-fold increase with GFP fusion) in RCSN-3 substantia nigra-derived cells significantly protects against aminochrome neurotoxicity; synaptic vesicle preparations from rat substantia nigra transport [³H]-aminochrome at rates similar to dopamine (ATP-dependent), with aminochrome uptake inhibited by lobeline but not reserpine, establishing VMAT2 as a protective transporter for aminochrome sequestration.\",\n      \"method\": \"Bicistronic plasmid overexpression of VMAT2-GFP; [³H]-aminochrome and [³H]-dopamine uptake in synaptic vesicles; transmission electron microscopy; ATP assay; DNA laddering\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro vesicle transport assay plus cell overexpression with functional outcome, single lab\",\n      \"pmids\": [\"22483869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VMAT2 undergoes retrograde trafficking to the trans-Golgi network in non-neuronal cells and interacts biochemically and subcellularly with Vps35, a key component of the retromer complex. siRNA knockdown of Vps35 alters VMAT2 subcellular localization and decreases VMAT2 protein stability (reduced half-life), identifying retromer-dependent retrograde trafficking as a regulator of VMAT2 stability.\",\n      \"method\": \"Biochemistry (co-immunoprecipitation); subcellular localization imaging; siRNA knockdown of Vps35; VMAT2 half-life measurement\",\n      \"journal\": \"Journal of biomedical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP plus siRNA functional study with localization, single lab, non-neuronal cell system\",\n      \"pmids\": [\"27924069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Selective knockout of Vmat2 in midbrain leptin receptor (LepR) neurons disrupts dopamine accumulation in vesicles without significantly altering evoked glutamate or GABA release to downstream neurons. Specific activation of midbrain LepR neurons promotes VMAT2-dependent feeding; KO mice resist high-fat diet-induced obesity, establishing that VMAT2-mediated monoamine (dopamine) release from midbrain LepR neurons regulates high-fat diet consumption and leptin's feeding effects.\",\n      \"method\": \"Conditional Vmat2 KO in LepR-Cre neurons; evoked neurotransmitter release measurement; optogenetic activation; feeding behavior and metabolic phenotyping\",\n      \"journal\": \"eNeuro\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional KO with optogenetics and feeding behavior, single lab\",\n      \"pmids\": [\"28560316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Genetic deletion of VMAT2 in dopaminergic neurons (homozygous KO) in primary mesencephalic cultures reduces dopamine transporter (DAT) activity without affecting TH-positive cell number; reserpine (VMAT2 inhibitor) likewise reduces DAT activity in WT and heterozygous cultures but not in homozygous KO cells, establishing that VMAT2 activity is required to maintain normal DAT function.\",\n      \"method\": \"Primary mesencephalic cultures from VMAT2 wild-type, heterozygous, and homozygous KO mice; DAT activity assays; reserpine pharmacology; synaptosomal DAT assays from neonatal mice\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus pharmacological confirmation, functional transport assay, single lab\",\n      \"pmids\": [\"17664021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Low-power laser irradiation (LPLI) protects SH-SY5Y cells against MPP+-induced neurotoxicity by activating ERK, which phosphorylates CREB at Ser133, increasing CREB binding to the VMAT2 promoter and upregulating VMAT2 expression, leading to increased dopamine release and cell survival. This established an ERK/CREB/VMAT2 transcriptional pathway regulating VMAT2.\",\n      \"method\": \"SH-SY5Y cell LPLI treatment; ERK/CREB phosphorylation (Western blot); chromatin immunoprecipitation (CREB binding to VMAT2 promoter); VMAT2 expression and dopamine release assays; cell viability\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for promoter binding plus pathway inhibitor experiments, single lab, cell line system\",\n      \"pmids\": [\"28627368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In Rho GTPase inhibition experiments in MN9D dopaminergic cells, inhibition of Rho (via C3 transferase or db-cAMP) decreased α-synuclein mRNA/protein via reduction of nuclear SRF and cytosolic retention of MKL-1, and concomitantly increased VMAT2 and SNARE proteins, demonstrating that Rho GTPase signaling inversely regulates α-synuclein and VMAT2 expression.\",\n      \"method\": \"MN9D cell treatment with Rho inhibitor C3 transferase and db-cAMP; Western blot and RT-PCR for α-synuclein and VMAT2; nuclear/cytosolic fractionation for SRF/MKL-1; siRNA knockdown of SRF\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple pharmacological and siRNA approaches, single lab, cell line system\",\n      \"pmids\": [\"21699982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"VMAT2 expression in pancreatic β-cells is co-localized with insulin in beta cells (but not in glucagon or somatostatin cells) in human and monkey pancreas; additionally, VMAT2 is expressed in some pancreatic polypeptide (PP) cells, particularly in the pancreatic head (~44–53% co-staining), limiting VMAT2's utility as a specific β-cell marker for PET imaging.\",\n      \"method\": \"Double-label immunofluorescence with antibodies to VMAT2, insulin, and PP; confocal microscopy of human pancreas subregions\",\n      \"journal\": \"Journal of molecular histology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — systematic immunofluorescence co-localization with quantification, single lab\",\n      \"pmids\": [\"18791800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Lithium ions (at therapeutic concentrations, ~1 mM) increase overall VMAT2 mRNA in rat brain (by ~199%), with region-specific differences: 50–100% increases in raphe nuclei, VTA, and substantia nigra, but ~50% decreases in locus coeruleus, suggesting VMAT2 expression is differentially regulated by lithium in distinct monoaminergic neuron populations.\",\n      \"method\": \"Dietary lithium supplementation in rats; Northern blot; in situ hybridization\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — in vivo pharmacological manipulation with regional mRNA quantification, single lab, two methods\",\n      \"pmids\": [\"12384252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"VMAT2 mRNA and protein are upregulated in rat adrenal chromaffin cells in response to repeated immobilization stress, and VMAT2 expression extends to PNMT-positive (epinephrine-synthesizing) chromaffin cells that normally do not express VMAT2, indicating stress-triggered adaptive expansion of VMAT2 expression to enhance catecholamine storage capacity.\",\n      \"method\": \"Rat immobilization stress model; Northern blot and RT-PCR for VMAT2 mRNA; immunofluorescence co-localization with TH and PNMT; Western blot\",\n      \"journal\": \"Cellular and molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — in vivo stress model with immunofluorescence and mRNA analysis, single lab, multiple methods\",\n      \"pmids\": [\"21046458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A new fluorescent VMAT2 substrate (FFN206) with apparent Km of 1.16 µM (similar to dopamine) localizes to VMAT2-expressing acidic compartments in intact cells and enables quantitative, high-throughput measurement of VMAT2 activity in VMAT2-transfected HEK cells (Z'-factor 0.7–0.8), validating VMAT2's substrate-binding and transport properties in a cell-based system.\",\n      \"method\": \"Fluorescent substrate synthesis; fluorescence microscopy; microplate reader assays; Km determination; VMAT2-transfected HEK cell assays\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with defined substrate kinetics, cell-based validation, single lab\",\n      \"pmids\": [\"23859623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"SLC18A2 promoter haplotypes show differential activity in vitro (~20% difference between two frequent haplotypes), and haplotypes containing -14234G and -2504C are associated with protection against alcoholism, identifying functional promoter variants that regulate VMAT2 transcription.\",\n      \"method\": \"Re-sequencing of 17.4 kb SLC18A2 promoter region; in vitro promoter activity assays; genotyping of hdSNPs; case-control association analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–3 / Moderate — in vitro promoter assay supported by genetic association, single lab\",\n      \"pmids\": [\"15829504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SLC18A2 is silenced in prostate cancer by DNA hypermethylation (in 88% of tumor samples) and allelic loss (LOH in 23%), and treatment with DNA methylation and HDAC inhibitors rescues VMAT2 expression in three prostate cancer cell lines, identifying epigenetic silencing as a mechanism of SLC18A2 inactivation.\",\n      \"method\": \"Bisulfite sequencing; expression and SNP microarrays; tissue microarray IHC; methylation and HDAC inhibitor rescue in cancer cell lines\",\n      \"journal\": \"Clinical cancer research : an official journal of the American Association for Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bisulfite sequencing with pharmacological rescue, multiple cell lines, single lab\",\n      \"pmids\": [\"19228741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Region-specific targeting of VMAT2 to somatodendritic tubulovesicles in VTA neurons was demonstrated by electron microscopic immunocytochemistry. In paranigral VTA, a higher percentage of VMAT2-labeled dendrites co-express D2 receptors compared to parabrachial VTA, while parabrachial VTA dendrites contain more VMAT2 immunogold deposits per cell, providing a cellular basis for regional heterogeneity in dopamine autoregulation.\",\n      \"method\": \"Electron microscopic immunocytochemistry with dual labeling for VMAT2 and D2R in VTA subdivisions\",\n      \"journal\": \"Synapse (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EM-level subcellular localization with quantitative comparison, single lab\",\n      \"pmids\": [\"12112404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A novel homozygous missense variant p.P316A in SLC18A2 causes brain monoamine vesicular transport disease with absent serotonin in platelet dense granules (demonstrated by electron microscopy and functional platelet aggregation assays), confirming that VMAT2 is required for serotonin storage in platelet dense granules as well as in brain synaptic vesicles.\",\n      \"method\": \"Whole genome sequencing; Sanger sequencing; platelet electron microscopy; platelet aggregation and ATP secretion assays\",\n      \"journal\": \"JIMD reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — human genetic variant with direct platelet functional readout (electron microscopy, aggregation assay), single case but direct mechanistic link\",\n      \"pmids\": [\"31240161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PACAP38 treatment increases VMAT2 expression and function in mouse striatum (at 28 days post-treatment), and genetic reduction of VMAT2 increases methamphetamine neurotoxicity, establishing that PACAP38 neuroprotection against METH is mediated at least partly by upregulating VMAT2 expression.\",\n      \"method\": \"Systemic PACAP38 administration in mice; VMAT2 expression assays; methamphetamine neurotoxicity challenge (striatal dopamine, GFAP, GLUT5); VMAT2 heterozygous KO comparison\",\n      \"journal\": \"Neuropeptides\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, indirect inference that VMAT2 increase mediates neuroprotection based on gene expression without direct mechanistic confirmation\",\n      \"pmids\": [\"18533255\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VMAT2 (SLC18A2) is a vesicular transporter that uses the proton electrochemical gradient across the synaptic vesicle membrane to package dopamine, serotonin, norepinephrine, histamine, and related monoamines (as well as the neurotoxin MPP+ and the reactive metabolite aminochrome) from the neuronal cytoplasm into secretory vesicles; its activity is regulated post-translationally by PKC-mediated phosphorylation of N-terminal Ser15/Ser18 (controlling methamphetamine-stimulated efflux), an intralumenal Cys126–Cys333 disulfide bond (required for efficient transport), JNK3-mediated inhibition (linking microtubule integrity to vesicular DA storage), and G-protein-dependent feedback (Gαo2 in neurons, Gαq in platelets) whereby vesicle filling triggers down-regulation of further uptake; transcription of SLC18A2 is driven by ERK/CREB signaling and is regulated by Rho GTPase/SRF pathways and lithium, and the gene is epigenetically silenced by DNA methylation in prostate cancer; in pancreatic β-cells VMAT2 sequesters dopamine to limit monoamine oxidase-generated ROS, protecting cells from oxidative stress; the Vps35 retromer complex controls retrograde trafficking of VMAT2 to maintain its protein stability; and loss of VMAT2 function—whether by genetic knockout, toxin inhibition, or disease-associated reduction—leads to elevated cytosolic monoamines, oxidative damage, and progressive catecholaminergic neurodegeneration.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SLC18A2 (VMAT2) is a vesicular transporter that packages cytoplasmic monoamines—dopamine, serotonin, noradrenaline, and histamine—into synaptic vesicles and secretory granules, and this sequestration is central to both neurotransmitter storage and protection of monoaminergic cells from cytotoxic insult [#0, #12, #24]. VMAT2 also transports the dopaminergic neurotoxin MPP+ and the reactive dopamine metabolite aminochrome, and the level of VMAT2 sets the size of the releasable vesicular and cytosolic monoamine pools, bidirectionally determining vulnerability to toxins: reduced VMAT2 exacerbates MPTP toxicity while overexpression confers protection [#0, #7, #8, #15]. Transport is supported by an intralumenal Cys126–Cys333 disulfide bond required for efficient monoamine uptake [#4]. VMAT2 activity is tuned post-translationally: PKC phosphorylation of the N-terminal Ser15/Ser18 controls monoamine sequestration and methamphetamine-stimulated efflux [#5]; JNK3 inhibits VMAT2 downstream of microtubule destabilization, linking cytoskeletal integrity to vesicular storage [#6]; and vesicle filling triggers heterotrimeric G-protein feedback that down-regulates further uptake (Gαo2 in serotonergic neurons, Gαq in platelets) [#2, #3]. VMAT2 protein stability is maintained by retromer-dependent retrograde trafficking through interaction with Vps35 [#16], and its expression is driven transcriptionally by an ERK/CREB pathway [#19]. Beyond the nervous system, VMAT2 in pancreatic β-cells sequesters dopamine to limit monoamine-oxidase-generated ROS and preserve β-cell function [#11], and is required for serotonin storage in platelet dense granules [#28]. Genetic loss in mice produces progressive multi-system catecholaminergic neurodegeneration with α-synuclein accumulation, and a homozygous p.P316A missense variant causes brain monoamine vesicular transport disease in humans [#9, #28].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing which cells store monoamines vesicularly required distinguishing VMAT2 from VMAT1; isoform-specific antibodies showed VMAT2 is the neuronal/sympathetic transporter while VMAT1 is endocrine, defining cell-type-specific monoamine storage.\",\n      \"evidence\": \"Isoform-specific antipeptide antibodies and immunohistochemistry on rat tissues and programmed fibroblasts\",\n      \"pmids\": [\"7654518\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish transport mechanism or kinetics\", \"Did not resolve subcellular vesicle targeting\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Whether vesicular sequestration is neuroprotective and behaviorally relevant was unknown; heterozygous knockout mice with halved VMAT2 showed enhanced amphetamine responses and greater MPTP-induced dopamine cell loss, establishing VMAT2 dosage as a determinant of neuroprotection and psychostimulant effects.\",\n      \"evidence\": \"VMAT2 knockout mouse with behavioral assays and MPTP neurotoxicity cell counting\",\n      \"pmids\": [\"9275230\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the post-translational regulators of VMAT2 activity\", \"Mechanism of MPP+ handling not biochemically resolved here\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"How vesicle filling is sensed and fed back to the transporter was unknown; Gαo2 (not Gαo1) was shown to down-regulate VMAT2 in serotonergic cells and to co-localize with VMAT2 on small synaptic vesicles, revealing G-protein-mediated autoregulation.\",\n      \"evidence\": \"Transport assays with pertussis toxin, EM co-localization, and synaptic vesicle uptake in serotonergic cells/neurons\",\n      \"pmids\": [\"10704487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal coupling vesicle content to Gαo2 activation not defined\", \"No structural basis for the regulatory interaction\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The structural features needed for efficient transport were unclear; a lumenal Cys126–Cys333 disulfide bond was identified, and cysteine-to-serine mutation reduced serotonin transport, defining a covalent structural requirement.\",\n      \"evidence\": \"Thrombin-cleavage mapping, non-reducing SDS-PAGE, site-directed mutagenesis, and [3H]serotonin transport assays\",\n      \"pmids\": [\"12009896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full structural model\", \"How the disulfide affects substrate translocation mechanically unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Whether autoregulation is conserved beyond neurons and which G-protein operates in platelets was open; vesicle filling with serotonin/noradrenaline triggered Gαq-mediated down-regulation, confirmed in Gαq knockout platelets, generalizing content-dependent feedback control.\",\n      \"evidence\": \"Permeabilized platelet transport assays, Tph1 and Gαq knockout reconstitution, GTP-analog activation\",\n      \"pmids\": [\"12604601\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular sensor coupling vesicle content to Gαq unknown\", \"Direct VMAT2–Gαq contact not demonstrated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Whether VMAT2 level sets the size of releasable dopamine pools was untested; mice with ~95% reduced VMAT2 had diminished vesicular DA stores, lower release, reduced amphetamine-evoked efflux, and autoreceptor supersensitivity.\",\n      \"evidence\": \"Fast cyclic voltammetry in striatal slices with pharmacological dissection in VMAT2-mutant mice\",\n      \"pmids\": [\"12716422\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address long-term neurodegenerative consequences\", \"Cytosolic monoamine toxicity not directly measured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Whether transporter targeting could be enhanced was explored; synaptophysin co-overexpression synergistically increased VMAT2-mediated protection against MPP+, implicating vesicle biogenesis partners in VMAT2 function.\",\n      \"evidence\": \"Stable co-overexpression of VMAT2 and synaptophysin in MN9D cells with MPP+ viability assays\",\n      \"pmids\": [\"16023584\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct measurement of VMAT2 vesicle targeting\", \"Overexpression cell-line context only\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Functional genetic variation regulating VMAT2 transcription was uncharacterized; promoter haplotypes differing ~20% in activity were linked to protection against alcoholism, identifying regulatory variants.\",\n      \"evidence\": \"Promoter resequencing, in vitro promoter activity assays, and case-control association\",\n      \"pmids\": [\"15829504\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal transcription factor binding the variant sites not defined\", \"Association not mechanistically tied to monoamine phenotype\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"A mechanism for age-related decline of vesicular uptake was lacking; aging rat VMAT2 was shown to deglycosylate and redistribute from vesicle to soluble fractions without total protein loss, suggesting post-translational decline.\",\n      \"evidence\": \"Subcellular fractionation and Western blot in young vs aged rat striatum\",\n      \"pmids\": [\"17582657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct activity assay confirming functional decline\", \"Enzymes mediating deglycosylation unidentified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Whether VMAT2 reciprocally controls plasma-membrane uptake was unknown; deletion or inhibition of VMAT2 reduced DAT activity without TH cell loss, establishing VMAT2 activity as required to maintain DAT function.\",\n      \"evidence\": \"Primary mesencephalic cultures from VMAT2 KO mice with reserpine pharmacology and DAT activity assays\",\n      \"pmids\": [\"17664021\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of VMAT2–DAT coupling not defined\", \"Single-lab cell-culture readout\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Whether disrupted vesicular storage alone causes Parkinsonian neurodegeneration was untested; ~95% VMAT2-deficient mice developed progressive catecholamine neuron loss with α-synuclein accumulation and multi-system deficits.\",\n      \"evidence\": \"Conditional VMAT2-deficient mouse with stereology, immunohistochemistry, and behavioral battery\",\n      \"pmids\": [\"21403896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal chain from cytosolic monoamines to α-synuclein aggregation not fully resolved\", \"Human disease relevance shown only later\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Transcriptional coupling of VMAT2 to disease-associated genes was unclear; Rho GTPase inhibition reciprocally increased VMAT2 and decreased α-synuclein via SRF/MKL-1, linking Rho signaling to VMAT2 expression.\",\n      \"evidence\": \"Rho inhibitor and db-cAMP treatment with fractionation and SRF siRNA in MN9D cells\",\n      \"pmids\": [\"21699982\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcription factor binding to the VMAT2 promoter not shown here\", \"Cell-line context only\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Whether VMAT2 protects against endogenous reactive dopamine metabolites was open; VMAT2 overexpression protected nigral cells against aminochrome and vesicles transported [3H]-aminochrome, identifying aminochrome as a VMAT2 substrate.\",\n      \"evidence\": \"VMAT2-GFP overexpression and [3H]-aminochrome/dopamine vesicle uptake with inhibitor profiling\",\n      \"pmids\": [\"22483869\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Aminochrome uptake inhibited by lobeline but not reserpine, raising unresolved transport-mode questions\", \"Single-lab system\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The contribution of the N-terminus to drug-evoked efflux was unknown; PKC phosphorylation of Ser15/Ser18 was shown to control monoamine sequestration and to be required for methamphetamine-stimulated efflux.\",\n      \"evidence\": \"N-terminal truncations, in vitro PKC assay, phospho-mimetic/null mutagenesis, and sequestration/efflux assays in transfected cells\",\n      \"pmids\": [\"24321511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of Ser15/Ser18 phosphorylation not established\", \"Conformational mechanism of efflux not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A quantitative cell-based readout of VMAT2 transport was needed; the fluorescent substrate FFN206 (Km ~1.16 µM) localized to VMAT2 acidic compartments and enabled high-throughput activity measurement, validating substrate-binding properties.\",\n      \"evidence\": \"Fluorescent substrate synthesis, microscopy, and microplate assays in VMAT2-transfected HEK cells\",\n      \"pmids\": [\"23859623\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not address physiological regulation\", \"Heterologous cell system only\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Whether VMAT2-controlled monoamines influence endocrine differentiation was unknown; VMAT2 inhibition promoted β-cell differentiation from progenitors and yielded transplantable insulin-producing cells, implicating monoamines as negative regulators of β-cell fate.\",\n      \"evidence\": \"Chemical screen with VMAT2 inhibitors in ES-cell differentiation and diabetic mouse transplantation\",\n      \"pmids\": [\"24316738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct monoamine signaling pathway in progenitors not fully mapped\", \"Pharmacological inhibitors may have off-target effects\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"How VMAT2 protein stability is maintained was unknown; VMAT2 was shown to undergo retromer-dependent retrograde trafficking via Vps35 interaction, with Vps35 knockdown reducing VMAT2 half-life.\",\n      \"evidence\": \"Co-immunoprecipitation, localization imaging, Vps35 siRNA, and VMAT2 half-life measurement in non-neuronal cells\",\n      \"pmids\": [\"27924069\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP without neuronal validation\", \"Degradation route of mislocalized VMAT2 not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Whether VMAT2 dosage bidirectionally sets toxin vulnerability was tested; on identical genetic background, VMAT2-LO mice showed exacerbated MPTP toxicity and progressive terminal loss while VMAT2-HI mice were protected.\",\n      \"evidence\": \"VMAT2-LO and VMAT2-HI transgenic mice with vesicular uptake assays and MPTP challenge\",\n      \"pmids\": [\"27287315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the molecular event triggering terminal degeneration\", \"Human relevance inferred indirectly\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A transcriptional pathway upregulating VMAT2 for neuroprotection was undefined; ERK-driven CREB phosphorylation increased CREB binding to the VMAT2 promoter and VMAT2 expression, protecting against MPP+.\",\n      \"evidence\": \"ERK/CREB phosphorylation, ChIP of CREB at the VMAT2 promoter, and viability assays in SH-SY5Y cells\",\n      \"pmids\": [\"28627368\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo validation lacking\", \"Cell-line and laser-stimulus-specific context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Whether VMAT2 loss causes human disease and platelet storage failure was open; a homozygous p.P316A variant caused brain monoamine vesicular transport disease with absent serotonin in platelet dense granules.\",\n      \"evidence\": \"Whole genome sequencing with platelet electron microscopy and aggregation/secretion assays\",\n      \"pmids\": [\"31240161\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single case\", \"Structural impact of P316A on transport not directly assayed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The protective role of VMAT2 in β-cells was unproven; β-cell-specific Vmat2 knockout elevated ROS and accelerated β-cell dysfunction under high-fat diet, showing VMAT2 sequesters dopamine to limit MAO-generated oxidative stress.\",\n      \"evidence\": \"β-cell-specific conditional KO mice with glucose/insulin tolerance tests, ROS measurement, and β-cell marker immunostaining\",\n      \"pmids\": [\"32826296\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of MAO-derived ROS vs other sources not isolated\", \"Human β-cell relevance not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Whether VMAT2 controls monoamine turnover and brain development was tested; zebrafish Vmat2 loss reduced monoamines while raising metabolites and altered Notch1a/Pax2a in proliferative zones, linking VMAT2 to monoamine turnover and developmental gene expression.\",\n      \"evidence\": \"CRISPR/Cas9 zebrafish knockout with HPLC, qPCR, in situ hybridization, and behavioral assays\",\n      \"pmids\": [\"34403568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking monoamine loss to developmental gene changes not defined\", \"Ortholog model may differ from mammalian regulation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the multiple post-translational regulators (PKC/Ser15-18, JNK3, the Cys126–Cys333 disulfide, Gαo2/Gαq feedback) integrate on a single VMAT2 molecule, and what high-resolution structural mechanism couples proton gradient to monoamine translocation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model integrating regulatory sites\", \"Sensor coupling vesicle content to G-protein feedback unidentified\", \"In vivo interplay of regulators untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 4, 7, 15, 24]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [0, 12, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [2, 14, 27]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [0, 7, 9]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [2, 16]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [11, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"VPS35\", \"GNAO1\", \"GNAQ\", \"SYP\", \"MAPK10\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}